Rani Therapeutics Holdings (RANI) Enterprise Value (2021 - 2026)

Rani Therapeutics Holdings has reported Enterprise Value for 6 years, with the latest figure at $97.6 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 429.23% year-over-year to $97.6 million in Q2 2026; TTM through Jun 2026 was $97.6 million, a 429.23% increase from a year earlier, with the FY2025 full-year figure at $154.0 million, up 101.67% from the prior year.
• Enterprise Value was $97.6 million for Q2 2026 at Rani Therapeutics Holdings, up from $96.9 million in the prior quarter.
• The five-year high for Enterprise Value was $613.1 million in Q1 2022, with the low at $18.4 million in Q2 2025.
• Average Enterprise Value over 5 years is $196.9 million, with a median of $155.5 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value plunged 90.32% in 2025, then jumped 429.23% in 2026.
• Over 5 years, Enterprise Value stood at $203.2 million in 2022, then decreased by 14.74% to $173.2 million in 2023, then sank by 55.91% to $76.4 million in 2024, then surged by 101.67% to $154.0 million in 2025, then tumbled by 36.64% to $97.6 million in 2026.
• The last three Enterprise Value figures came in at $97.6 million (Q2 2026), $96.9 million (Q1 2026), and $154.0 million (Q4 2025), per Business Quant data.